Anika Therapeutics, Inc. (ANIK) Tops Q2 EPS by 3c, Revenue Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.42 +1.56%
EPS Growth %: +950.0%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +950.0%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $26.3 million versus the consensus estimate of $28.2 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Truist names top clean energy stocks to watch ahead of Q3 earnings season
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
